Lexaria Bioscience Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Lexaria Bioscience de 23.7% y 74.3% respectivamente, mientras que el BPA crecerá en un 29.9% al año.

Información clave

23.7%

Tasa de crecimiento de los beneficios

29.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	27.4%
Tasa de crecimiento de los ingresos	74.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	21 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Lexaria Bioscience gets third patent granted in Japan

Jul 14

Lexaria Bioscience's DehydraTECH licensee Cannadips expands internationally

Jul 07

Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans?

Apr 15

We Think Lexaria Bioscience (NASDAQ:LEXX) Can Afford To Drive Business Growth

Dec 07

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:LEXX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
8/31/2026	1	-9	N/A	N/A	2
8/31/2025	0	-7	N/A	N/A	2
8/31/2024	0	-5	N/A	N/A	2
2/29/2024	0	-5	-5	-5	N/A
11/30/2023	0	-6	-6	-6	N/A
8/31/2023	0	-7	-6	-6	N/A
5/31/2023	0	-7	-6	-5	N/A
2/28/2023	0	-7	-5	-5	N/A
11/30/2022	0	-7	-5	-5	N/A
8/31/2022	0	-7	-5	-5	N/A
5/31/2022	0	-7	-5	-5	N/A
2/28/2022	0	-7	-5	-5	N/A
11/30/2021	0	-7	-5	-4	N/A
8/31/2021	1	-6	-4	-4	N/A
5/31/2021	1	-5	-4	-3	N/A
2/28/2021	1	-4	-3	-3	N/A
11/30/2020	1	-4	-3	-3	N/A
8/31/2020	0	-4	-3	-3	N/A
5/31/2020	0	-4	-3	-3	N/A
2/29/2020	0	-4	-3	-3	N/A
11/30/2019	0	-4	-4	-3	N/A
8/31/2019	0	-4	-4	-3	N/A
5/31/2019	0	-4	-4	-3	N/A
2/28/2019	0	-6	-3	-3	N/A
11/30/2018	0	-7	-3	-3	N/A
8/31/2018	0	-7	-3	-3	N/A
5/31/2018	0	-6	-2	-2	N/A
2/28/2018	0	-3	-2	-2	N/A
11/30/2017	0	-2	N/A	-2	N/A
8/31/2017	0	-2	N/A	-2	N/A
5/31/2017	0	-1	N/A	-1	N/A
2/28/2017	0	-1	N/A	-1	N/A
11/30/2016	0	-1	N/A	-1	N/A
8/31/2016	0	-1	N/A	-1	N/A
5/31/2016	0	-1	N/A	-1	N/A
2/29/2016	0	-2	N/A	-1	N/A
11/30/2015	0	-2	N/A	-2	N/A
8/31/2015	0	-2	N/A	-2	N/A
5/31/2015	0	-2	N/A	-1	N/A
2/28/2015	0	-2	N/A	-1	N/A
11/30/2014	N/A	-2	N/A	-1	N/A
8/31/2014	N/A	-2	N/A	-1	N/A
7/31/2014	1	-1	N/A	0	N/A
4/30/2014	1	-1	N/A	0	N/A
1/31/2014	1	0	N/A	0	N/A
10/31/2013	N/A	-1	N/A	0	N/A
7/31/2013	1	0	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que LEXX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que LEXX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que LEXX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (74.3% al año) de LEXX crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (74.3% al año) de LEXX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de LEXX se prevé que sea elevada dentro de 3 años.

Lexaria Bioscience Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 24%

Consensus revenue estimates increase by 100%

Consensus revenue estimates decrease by 20%, EPS upgraded

Consensus revenue estimates increase by 38%, EPS downgraded

Consensus revenue estimates fall by 65%

Price target decreased to US$15.00

Recent updates

Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Lexaria Bioscience Receives Nasdaq Bid Price Deficiency Notice

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

Lexaria Bioscience Corp. Announces Chief Financial Officer Changes

Lexaria Bioscience Corp. Discovers That DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

Lexaria Bioscience Corp. Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

Lexaria Bioscience Corp. Announces Batch Manufacturing of the DehydraTECH™-Processed Cannabidiol

Lexaria Bioscience Corp. has completed a Composite Units Offering in the amount of $2.0007 million.

Lexaria Bioscience Corp. has completed a Composite Units Offering.

Lexaria Bioscience Corp. Human Clinical Nicotine Study Completes Dosing as Planned

Consensus revenue estimates fall by 65%

Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2022)

Lexaria Bioscience Corp. Appoints Julian Gangolli as Strategic Advisor

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.35 loss in 1Q 2022)

Lexaria Bioscience Corp.'s DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels

Lexaria Bioscience Corp. Human Oral Nicotine Study Begins Dosing

Lexaria Bioscience Corp. Enhances Performance Compared to Epidiolex in Seizure Study Program

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$15.00

Lexaria Bioscience Corp. Announces Examining Potential Therapeutic Use of Dehydratech-Cbd in Dementia

Lexaria Bioscience Corp. Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes

Lexaria Receives Independent Review Board Approval for Its Upcoming Human Oral Nicotine Study

Lexaria Bioscience Corp. Announces That Human Clinical Study Hyper-H21-4 the Worlds First Study to Evidence A Sustained Drop in Bp in Normally Active Hypertensive Patients

Lexaria Bioscience Corp. Appoints Dr. Catherine Turkel to its Board of Directors

Lexaria Bioscience Corp. Receives Positive Full Written Response from the Food and Drug Administration from Its Pre-Investigational New Drug

Consensus EPS estimates fall by 11%

Lexaria Bioscience Corp. Announces Dosing with Lexaria's DehydraTECH-Processed Cannabidiol Is Completed

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. Announces That It Has Been Notified of the Allowance of Its 26Th Worldwide Patent with A New Patent to Be Granted in Japan

Lexaria Bioscience Corp. Announces the Pending Start of Its Upcoming Human Nicotine Study Nic-H22-1

Lexaria Bioscience gets third patent granted in Japan